Share This Article:

Pharmacological evaluation of a novel enhydrazone ester (CEE-1) as a dual inhibitor of the release of pro-inflammatory cytokines and prostanoids from human monocytes

Full-Text HTML XML Download Download as PDF (Size:637KB) PP. 54-63
DOI: 10.4236/abb.2013.48A2008    2,148 Downloads   3,420 Views   Citations

ABSTRACT

CEE-1 (ethyl 4-phenylhydrazinocyclohex-3-en-2-oxo-6-phenyl-1-oate)a novel enhydrazone ester, was tested in vitro for anti-inflammatory activity against the release of pro-inflammatory cytokine and prostanoid from lipopolysaccharide-activated human monocytes or human monocytic cell line (U937). The effects were compared with those of standard anti-inflammatory drugs dexamethasone and indomethacin. CEE-1 potently and strongly inhibited the release of both tumor necrosis factor-alpha (TNF-α) and prostaglandin E2 (PGE2). The concentrations producing 50% inhibition (IC50 values) were 2.0 μM and 2.4 μM for TNF-α and PGE2, respectively. At 30 μM, the drug achieved almost complete inhibition of both mediators. Dexamethasone had similar effects but indomethacin inhibited only the PGE2 release, and although CEE-1 was less potent than these two drugs, it had comparable efficacy. The compound appeared to act, at least, in part by inhibiting the up-regulation of the mRNA for TNF-α as well as that of the prostanoid-synthetic enzyme, cyclo-oxygenase-2 (COX-2). However, like dexamethasone, but unlike indomethacin, CEE-1 did not affect COX-2 enzyme function. Thus, the profile of activity of CEE-1 is similar to that of steroids rather than the non-steroidal anti-inflammatory drugs. Structure-activity study showed that the presence of a simple aromatic ring attached via an NH-NH group was critical for activity. At the concentrations that completely inhibited mediator release, the compound displayed no significant in vitro toxicity on the cells. These results show that CEE-1 is a dual inhibitor of the release of cytokines and prostanoids, and therefore could be a potential alternative to steroids in the treatment of inflammatory diseases.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Ezeamuzie, C. , Zamil, H. , Al-Baghli, H. and Edafiogho, I. (2013) Pharmacological evaluation of a novel enhydrazone ester (CEE-1) as a dual inhibitor of the release of pro-inflammatory cytokines and prostanoids from human monocytes. Advances in Bioscience and Biotechnology, 4, 54-63. doi: 10.4236/abb.2013.48A2008.

References

[1] Barnes, P.J. (2008) Immunology of asthma and chronic obstructive pulmonary disease. Nature Reviews Immunology, 8, 183-192. doi:10.1038/nri2254
[2] Cooles, F.A. and Isaacs, J.D. (2011) Pathophysiology of rheumatoid arthritis. Current Opinion in Rheumatology, 23, 233-240. doi:10.1097/BOR.0b013e32834518a3
[3] Homey, B., Steinhoff, M., Ruzicka, T. and Leung, D.Y. (2006) Cytokines and chemokines orchestrate atopic skin inflammation. Journal of Allergy and Clinical Immunology, 118, 178-189. doi:10.1016/j.jaci.2006.03.047
[4] Ohman, L. and Simren, M. (2010) Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nature Reviews Gastroenterology & Hepatology, 7, 163-173. doi:10.1038/nrgastro.2010.4
[5] Fujiwara, N. and Kobayashi, K. (2005) Macrophages in inflammation. Current Drug Targets—Inflammation & Allergy, 4, 281-286. doi:10.2174/1568010054022024
[6] Borish, L.C. and Steinke, J.W. (2003) Cytokines and chemokines. Journal of Allergy and Clinical Immunology, 111, S460-475. doi:10.1067/mai.2003.108
[7] Rahman, I. (2002) Oxidative stress and gene transcription in asthma and chronic obstructive pulmonary disease: Antioxidant therapeutic targets. Current Drug Targets— Inflammation & Allergy, 1, 291-315. doi:10.2174/1568010023344607
[8] Fogh, K. and Kragballe, K. (2000) Eicosanoids in inflammatory skin diseases. Prostaglandins & Other Lipid Mediators, 63, 43-54. doi:10.1016/S0090-6980(00)00096-4
[9] Case, J.P. (2001) Old and new drugs used in rheumatoid arthritis: A historical perspective. American Journal of Therapeutics, 8, 123-143. doi:10.1097/00045391-200103000-00007
[10] Loung, B.T., Chong, B.S. and Lowder, D.M. (2000) Treatment options for rheumatoid arthritis: Celecoxib, leflunomide, etanercept, and infliximab. The Annals of Pharmacotherapy, 34, 743-760. doi:10.1345/aph.19344
[11] Walsh, G.M. (2011) Novel cytokine-directed therapies for asthma. Discovery Medicine, 11, 283-291.
[12] Afeltra, A. (2001) Treatment of rheumatoid arthritis: New therapeutic approaches with biological agents. Endocrine, Metabolic & Immune Disorders-Drug Targets, 1, 45-65. doi:10.2174/1568008013341677
[13] Ito, K. (2006) Update on glucocorticoid action and resistance. Journal of Allergy and Clinical Immunology, 117, 522-543. doi:10.1016/j.jaci.2006.01.032
[14] Strehl, C., Spies, C.M. and Buttgereit, F. (2011) Pharmacodynamics of glucocorticoids. Clinical and Experimental Rheumatology, 29, S13-S18.
[15] Schacke, H., Docke, W.D. and Asadullah, K. (2002) Mechanisms involved in the side effects of glucocorticoids. Pharmacology & Therapeutics, 96, 23-43. doi:10.1016/S0163-7258(02)00297-8
[16] Ezeamuzie, C.I. and Edafiogho, I.O. (2012) Enhydrazone esters for treating asthma, allergy and inflammation. US Patent No. 8,324,422 B2.
[17] Edafiogho, I.O., Kombian, S.B., Ananthalakshmi, K.V., Salama, N.N., Eddington, N.D., Wilson, T.L., et al. (2007) Enaminones: Exploring additional therapeutic activities. Journal of Pharmaceutical Sciences, 96, 2509-2531. doi:10.1002/jps.20967
[18] Edafiogho, I.O., Phillips, O.A., Udo, E.E., Samuel, S. and Rethish, B. (2009) Synthesis, antibacterial and anticonvulsant evaluations of some cyclic enaminones. European Journal of Medicinal Chemistry, 44, 967-975. doi:10.1016/j.ejmech.2008.07.005
[19] El-Hashim, A., Yousefi, S., Edafiogho, I., Raghupathy, R., Yousif, M. and Simon, H.-U. (2010) Anti-inflammatory and immunosuppressive effects of the enaminone E121. European Journal of Pharmacology, 632, 73-78. doi:10.1016/j.ejphar.2009.12.004
[20] El-Hashim, A.Z., Edafiogho, I.O., Jaffal, S.M., Yousif, M.H., Ezeamuzie, C.I. and Kombian, S.B. (2011) Antitussive and bronchodilatory mechanisms of action for the enaminone E121. Life Sciences, 89, 378-387. doi:10.1016/j.lfs.2011.07.007
[21] Ezeamuzie, C.I. and Shihab, P.K. (2010) Interactions between theophylline and salbutamol on cytokine release in human monocytes. Journal of Pharmacology and Experimental Therapeutics, 334, 302-309. doi:10.1124/jpet.109.163238
[22] Cox, C.E. (2012) Persistent systemic inflammation in chronic critical illness. Respiratory Care, 57, 859-864. doi:10.4187/respcare.01719
[23] Franks, A.L. and Slansky, J.E. (2012) Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer. Anticancer Research, 32, 1119-1136.
[24] Gotzche, P. (2002) Non-steroidal anti-inflammatory drugs. Clinical Evidence, 8, 1203-1211.
[25] Rothstein, R. (1998) Safetyt profiles of leading non-steroidal anti-inflammatory drugs. American Journal of Medicine, 105, 39S-43S. doi:10.1016/S0002-9343(98)00280-0
[26] Katsanou, V., Dimitriou, M. and Kontoyiannis, D.L. (2006) Post-transcriptional regulators in inflammation: Exploring new avenues in biological therapeutics. Ernst Schering Foundation Symposium Proceedings, 4, 37-57.
[27] Stellato, C. (2004) Post-transcriptional and non-genomic effects of glucocorticoids. Proceedings of the American Thoracic Society, 1, 255-263. doi:10.1513/pats.200402-015MS

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.